Eastern Capital Ltd Reported increased Tapimmune Inc’s Stake

May 16, 2018 - By Adrian Erickson

TapImmune, Inc. (NASDAQ:TPIV) Logo

Eastern Capital Ltd Reported increased Stake in Tapimmune Inc

Eastern Capital Ltd filed with SEC a SC 13D/A form for Tapimmune Inc. It can be found at: 000140840818000005. As reported by Eastern Capital Ltd, the filler increased its stake in the stock by 24.53 % for 5,300,002 shares. Eastern Capital Ltd currently owns 38.8% of the stock. Date of activity: May14, 2018.

Reasons Why Eastern Capital Ltd Holds Tapimmune Inc

Item 4.Purpose of Transaction

On May 14, 2018, Eastern CapitalLimited entered into a Common Stock Purchase Agreement with the Issuer to purchase 1,300,000 shares of common stock at a priceper share of $2.40.

The Reporting Persons acquiredthe Issuer’s securities for investment purposes.

The Reporting Persons currentlyhave no plans or proposals which relate to or would result in any transaction, event or action enumerated in paragraphs (a) through(j) of Item 4 of Schedule 13D.

CUSIP No. 876033408 Page 6 of 8

SEC Form 13D.

The stock increased 7.59% or $0.23 during the last trading session, reaching $3.26. About 153,209 shares traded or 262.58% up from the average. TapImmune, Inc. (NASDAQ:TPIV) has declined 26.26% since May 17, 2017 and is downtrending. It has underperformed by 37.81% the S&P500.

TapImmune, Inc., a clinical-stage immuno-oncology company, develops peptide and gene immunotherapeutics and vaccines for the treatment of cancer and metastatic disease. The company has market cap of $34.64 million. It specializes in the development of immunotherapies targeting women's cancers advancing multiple Phase II and Phase Ib/II clinical studies for the treatment of ovarian and breast cancers. It currently has negative earnings. The company's peptide-or nucleic acid immunotherapeutic products comprise one or multiple naturally processed epitopes designed to comprehensively stimulate a patient's killer T cells and helper T cells, and to restore or further augment antigen presentation by using proprietary nucleic acid expression systems.

More notable recent TapImmune, Inc. (NASDAQ:TPIV) news were published by: Prnewswire.com which released: “TapImmune to Present at 2018 Disruptive Growth & Healthcare Conference” on May 01, 2018, also Prnewswire.com with their article: “TapImmune to Present at 2018 NYC Oncology Investor Conference” published on May 07, 2018, Prnewswire.com published: “TapImmune Creates Scientific Advisory Board to Support Clinical Development of Multi-Antigen Cell Therapy Platform” on May 16, 2018. More interesting news about TapImmune, Inc. (NASDAQ:TPIV) were released by: Prnewswire.com and their article: “TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno …” published on May 15, 2018 as well as Benzinga.com‘s news article titled: “32 Stocks Moving In Tuesday’s Mid-Day Session” with publication date: May 01, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.